Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | PAO and PFO | February 06, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date February 06, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,506 |
Ending reported balance
After 2026-02-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-06 · Sale · Disposed 29,951 · Balance 156,779 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Row 2 · 2026-02-09 · Sale · Disposed 3,379 · Balance 153,400 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Row 3 · 2026-02-10 · Sale · Disposed 6,894 · Balance 146,506 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 11, 2026 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,894 | $2.42 | $16,699.34 |
DisclosureSEC source: 0002018766-26-000006 · wk-form4_1770775823.xml · nonDerivative · entry 3 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,506 F2 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,379 | $2.39 | $8,085.61 |
DisclosureSEC source: 0002018766-26-000006 · wk-form4_1770775823.xml · nonDerivative · entry 2 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,400 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 29,951 | $2.43 | $72,771.94 |
DisclosureSEC source: 0002018766-26-000006 · wk-form4_1770775823.xml · nonDerivative · entry 1 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,779 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 01:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 556 | $2.52 | $1,398.34 |
DisclosureSEC source: 0002018766-26-000004 · wk-form4_1770254867.xml · nonDerivative · entry 2 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,730 F2 · shares: This sale was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,540 | $2.55 | $6,477.00 |
DisclosureSEC source: 0002018766-26-000004 · wk-form4_1770254867.xml · nonDerivative · entry 1 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,286 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 01:36 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0002018766-26-000002 · wk-form4_1768008966.xml · derivative · entry 1 Vultaggio Vincent · CIK 0002018766 · PAO and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Stock Option · 100,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:33 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 35,633 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001725160-25-000043 · wk-form4_1738798376.xml · derivative · entry 3 Vultaggio Vincent · CIK 0002018766 · PAO and Interim PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,633 Underlying: Common Stock · 35,633 shares Expires 2035-02-02 F3 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:33 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,615 | $1.71 | $4,475.57 |
DisclosureSEC source: 0001725160-25-000043 · wk-form4_1738798376.xml · nonDerivative · entry 2 Vultaggio Vincent · CIK 0002018766 · PAO and Interim PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,826 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:33 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 158,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000043 · wk-form4_1738798376.xml · nonDerivative · entry 1 Vultaggio Vincent · CIK 0002018766 · PAO and Interim PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,441 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| October 04, 2024 Filed Oct 4, 2024 22:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,603 | $3.18 | $5,097.54 |
DisclosureSEC source: 0001725160-24-000163 · wk-form4_1728079274.xml · nonDerivative · entry 1 Vultaggio Vincent · CIK 0002018766 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,855 F1 · kind: A portion of the shares were sold automatically to satisfy withholding tax obligations upon the vesting of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on September 20, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.